Anti-MAG Neuropathy PBMC
About:Anti-MAG Neuropathy PBMC samples are isolated from consented donors with clinically confirmed anti-myelin-associated glycoprotein (MAG) neuropathy. Ideal for studying the clonal IgM-producing B-cell population, BCR repertoire, T-cell responses, and immune mechanisms in peripheral nerve demyelination.
About Anti-MAG Neuropathy PBMC
Anti-MAG Neuropathy PBMC for Autoimmune Demyelinating Neuropathy Research
Anti-MAG Neuropathy PBMC products are sourced from IRB-consented donors clinically diagnosed with anti-MAG neuropathy and processed under stringent conditions within 24 hours of collection. Anti-MAG neuropathy is an autoimmune peripheral neuropathy in which a monoclonal IgM autoantibody binds myelin-associated glycoprotein (MAG) in peripheral nerve myelin, producing a chronic, predominantly demyelinating and often distal, sensory-predominant neuropathy. These cryopreserved peripheral blood mononuclear cells give access to the clonal B-cell population that produces the pathogenic IgM.
Disease Biology and Why PBMC
- IgM anti-MAG autoantibody is the defining feature; it is typically produced by a clonal B-cell or plasma-cell population, frequently in the setting of an IgM monoclonal gammopathy (MGUS) or, less often, Waldenström macroglobulinaemia.
- Clonal B cells are the therapeutic target: PBMCs allow identification, sorting, and immunoglobulin gene sequencing of the responsible clone, which is not possible from acellular matrices.
- B-cell depletion research: rituximab and other anti-CD20 or BTK-directed strategies aim at this clone; PBMCs support target expression, depletion, and repopulation studies.
- Complement-dependent myelin injury: anti-MAG IgM deposition with complement activation causes widening of myelin lamellae, linking B-cell output to the pathological lesion.
- Repertoire and clonality analysis: BCR sequencing and MYD88 L265P assessment in the B-cell compartment are informative for classifying the underlying lymphoproliferative process.
- T-cell and innate compartments can be profiled in parallel to study help for clonal IgM production and comparison with other inflammatory neuropathies.
Donor Stratification Available
- Anti-MAG IgM titre where available
- Underlying haematological context: IgM MGUS, Waldenström macroglobulinaemia, or no detectable paraprotein
- Monoclonal protein isotype and light chain
- Clinical severity and pattern: sensory-predominant, sensorimotor, or with prominent ataxia or tremor
- Treatment status: rituximab or other anti-CD20 therapy, BTK inhibitor, chemoimmunotherapy, IVIg, or treatment-naive
- Disease duration and time since diagnosis
- Matched healthy controls available
Product Features
- Research Use Only (RUO), cryopreserved PBMCs
- Clinically confirmed anti-MAG neuropathy donors
- Processed within 24 hours of collection
- Stored using CryoStor® CS10 freezing media
- IRB-approved protocols and electronic informed consent
- Custom aliquots available upon request
De-identified Donor Data
- Verified anti-MAG neuropathy diagnosis
- Anti-MAG antibody and paraprotein results where available
- Donor demographics: age, sex assigned at birth, race/ethnicity
- Self-reported allergies and infectious disease history
- Additional anti-MAG neuropathy-specific data available upon request
Applications
- Clonal B-cell identification, sorting, and immunophenotyping by flow or mass cytometry
- B-cell receptor repertoire sequencing and clonality analysis
- Single-cell RNA sequencing and bulk transcriptomic profiling
- B-cell depletion and BTK inhibitor target validation
- Autoantibody-producing cell characterisation and in vitro IgM secretion assays
- Immune pathway analysis in demyelinating neuropathy
- Genomic DNA extraction for MYD88 and related variant analysis
- Biomarker discovery, drug screening, and therapeutic development
Other Anti-MAG Neuropathy Specimen Types
Anti-MAG neuropathy donor material is also available as Anti-MAG Neuropathy Serum, Anti-MAG Neuropathy Plasma, and Anti-MAG Neuropathy Whole Blood. Serum and plasma are the appropriate matrices for anti-MAG IgM titration.
Compliance and Quality Assurance
- IRB-approved collections and protocols
- 21 CFR Part 11 – compliant e-consent system
- HIPAA-compliant donor data protection
Ordering & Customization
Anti-MAG Neuropathy PBMC samples are shipped on dry ice and available in standard or custom aliquots. For pricing, international orders, or regulatory requirements, please contact learnmore@sanguinebio.com to confirm documentation and compliance needs. Browse all human PBMCs or request a custom disease-state collection.
Applications
- Immunology and translational research
- Biomarker discovery and validation
- Drug screening and assay development
- Vaccine and infectious disease research
Product Features
- Research Use Only (RUO), PBMC
- Sourced from screened, consented donors
- Processed under validated SOPs
- QC tested for purity, viability, and sterility
- Processed within 24 hours of collection
- IRB-approved protocols with electronic informed consent
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human PBMC are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Download
PBMC Isolation from Whole Blood
Standard operating procedure for isolating peripheral blood mononuclear cells from whole blood using density-gradient separation.
-
Download
Immune Cell Isolation
Guidelines for isolating immune cell populations with validated enrichment steps, purity checkpoints, and documentation.
-
Download
Choosing the Right PBMC Configuration
Reference guide comparing PBMC formats, cryopreservation states, and study-fit recommendations for your application.
-
Download
Thawing Cryopreserved PBMC
Validated thawing protocol to recover viable cryopreserved PBMCs while minimizing activation and loss of function.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
PBMC
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Pair with a Healthy Control
Match your Anti-MAG Neuropathy PBMC with normal donor samples for comparison
Healthy Donor PBMCs
705 In Stock View InventoryNeed a custom PBMC cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.